138 related articles for article (PubMed ID: 30914605)
1. [Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib].
Takeda Y; Ohmura Y; Katsura Y; Sakamoto T; Nose Y; Mori R; Inatome J; Kawai K; Naito A; Murakami K; Kagawa Y; Masuzawa T; Takeno A; Egawa C; Murata K
Gan To Kagaku Ryoho; 2019 Mar; 46(3):532-536. PubMed ID: 30914605
[TBL] [Abstract][Full Text] [Related]
2. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Maida M; Macaluso FS; Valenza F; Virdone R
J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
[TBL] [Abstract][Full Text] [Related]
3. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
Kim Y; Hosoda Y; Kakita N; Yamada Y; Yamasaki M; Nishino M; Okano M; Nagai K; Yasui M; Tsujinaka T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2124-6. PubMed ID: 25731444
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.
Zhang Y; Fan W; Zhu K; Lu L; Fu S; Huang J; Wang Y; Yang J; Huang Y; Yao W; Li J
Oncotarget; 2015 Sep; 6(27):24550-9. PubMed ID: 26093084
[TBL] [Abstract][Full Text] [Related]
6. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
Liu D; Liu A; Peng J; Hu Y; Feng X
Eur J Med Res; 2015 Feb; 20(1):12. PubMed ID: 25649133
[TBL] [Abstract][Full Text] [Related]
7. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Hagihara A; Teranishi Y; Kawamura E; Fujii H; Iwai S; Morikawa H; Enomoto M; Tamori A; Kawada N
Intern Med; 2013; 52(14):1589-92. PubMed ID: 23857091
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
10. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.
Kirstein MM; Schweitzer N; Schmidt S; Klöpper A; Ringe KI; Lehmann U; Manns MP; Wedemeyer H; Vogel A
Acta Gastroenterol Belg; 2014 Dec; 77(4):386-8. PubMed ID: 25682626
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Doyle A; Marsh P; Gill R; Rodov M; Mohsen W; Varma P; Hong T; Strasser SI; Bell S; Ryan M; Nicoll A; Lubel J; Gow PJ; Fink MA; Roberts S; Kemp W; Kronborg I; Arachchi N; Knight V; Dev A
Scand J Gastroenterol; 2016 Aug; 51(8):979-85. PubMed ID: 27161568
[TBL] [Abstract][Full Text] [Related]
13. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
14. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
Huang YK; Yen CL; Shiu SI; Lee SW; Chang PY; Yeh HZ; Lee TY
PLoS One; 2017; 12(11):e0188999. PubMed ID: 29190692
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
[TBL] [Abstract][Full Text] [Related]
17. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
Takeda H; Nishikawa H; Osaki Y; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
Liver Int; 2015 May; 35(5):1581-9. PubMed ID: 24836552
[TBL] [Abstract][Full Text] [Related]
18. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Ye SL; Yang J; Bie P; Zhang S; Chen X; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Lv Z
BMC Cancer; 2018 Mar; 18(1):247. PubMed ID: 29499662
[TBL] [Abstract][Full Text] [Related]
19. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
Kitajima T; Hatano E; Mitsunori Y; Taura K; Fujimoto Y; Mizumoto M; Okajima H; Kaido T; Minamiguchi S; Uemoto S
Clin J Gastroenterol; 2015 Oct; 8(5):300-5. PubMed ID: 26249525
[TBL] [Abstract][Full Text] [Related]
20. Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature.
Futsukaichi Y; Tajiri K; Kobayashi S; Nagata K; Yasumura S; Takahara T; Minemura M; Yasuda I
Clin J Gastroenterol; 2019 Apr; 12(2):128-134. PubMed ID: 30374884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
